Background: Metabolic homeostasis is central to normal cardiac function. The molecular mechanisms underlying metabolic plasticity in the heart remain poorly understood. Results: Kruppel-like factor 15 (KLF15) is a direct and independent regulator of myocardial lipid flux. Conclusion: KLF15 is a core component of the transcriptional circuitry that governs cardiac metabolism. Significance: This work is the first to implicate the KLF transcription factor family in cardiac metabolism.
The working mammalian heart requires enormous amounts of energy to maintain contractile function and blood flow. Under physiologic conditions, the majority this energy production is derived from oxidative catabolism of fatty acids (FAs) 3 (ϳ70%), with the remainder being derived from glucose (ϳ20%) and other substrates, such as lactate and ketones (ϳ10%) (1) . In order to maintain contractile performance under a wide range of physiologic and pathophysiologic settings, the myocardium has evolved critical molecular mechanisms that match fuel supply with energy demand and nutrient availability (2) (3) (4) .
A major form of the heart's metabolic plasticity is its ability to augment lipid utilization as a means to guard against energy depletion and circulatory failure during periods of transient carbohydrate deprivation (e.g. fasting) or heightened energy needs (e.g. exercise, postnatal growth). Defects in specific genes critical for efficient myocardial lipid utilization are known to cause metabolic cardiomyopathies in both animal models and humans (5) . In addition, loss of metabolic plasticity has been observed in common forms of human heart failure (5) (6) (7) (8) , a leading cause of hospitalization and death worldwide (5) . Importantly, recent studies strongly support the contention that dysregulated lipid utilization and energy homeostasis play a causal role in heart failure progression (9, 10) . As recently highlighted by Goldberg et al. (2) , although the heart is far and away the most energy-requiring organ in the body, studies of cardiac lipid metabolism, especially in vivo are relatively scarce compared with investigations in adipose tissue, liver, or skeletal muscle. A better understanding of the fundamental mechanisms governing metabolic plasticity in the myocardium may therefore provide key insights into heart failure pathogenesis and pave the way for novel therapeutic approaches for this common and lethal condition.
Efficient myocardial lipid flux involves coordination of several key enzymatic steps, including sarcolemmal FA uptake and activation, maintenance of the intracellular triglyceride (TG) pool, acyl-CoA import into the mitochondrial matrix, ␤-oxidation, TCA cycle, and oxidative phosphorylation (1, 2, 5, 11) . The enzymatic machinery regulating each of these steps is under robust allosteric and transcriptional control in a manner that tightly couples lipid flux with energy demand and nutrient availability (12, 13) . Despite the fundamental importance of metabolic plasticity in the heart, there is surprisingly little known about the transcriptional pathways that directly regulate myocardial substrate flux. When compared with the vast body of work that has defined gene-regulatory networks governing myocyte hypertrophy (14) , the identification of transcription factors that are bona fide and direct regulators of myocardial nutrient flux is limited to a few members of the nuclear receptor superfamily (PPARs and ERRs) and the forkhead box factor FoxO1 (12, (15) (16) (17) .
Kruppel-like factors (KLFs) are DNA-binding transcriptional regulators that contain three conserved zinc fingers within the carboxyl terminus that bind a putative consensus 5Ј-C(A/T)CCC-3Ј motif in the promoters and enhancers of various genes (18, 19) . The amino terminus is involved in transcriptional activation and repression as well as protein-protein interaction. Previous studies from our group have defined KLF15 as a transcriptional repressor of pathologic cardiac hypertrophy (20 -22) . In contrast, the broad transcriptional programs directly regulated by KLF15 in the heart remain unknown.
Initial insights linking the KLF transcription factor family to metabolic homeostasis were gleaned from our studies defining KLF15 as a regulator of adipogenesis (23) . Subsequent studies in liver and skeletal muscle in the context of circadian cycles, fasting, and exercise now identify KLF15 as a central component of the transcriptional circuitry that regulates physiologic flux of all three major nutrient classes (glucose, lipids, and amino acids) (24 -26) . Despite these important observations, no role for any member of the KLF family in cardiac metabolism has been elucidated.
Here, we demonstrate that Kruppel-like factor 15 (KLF15) is a direct and independent regulator of myocardial lipid flux in vivo through a molecular mechanism involving recruitment of the chromatin remodeling enzyme p300 to target promoters. This study introduces an entirely new class of transcriptional regulators (KLFs) to the core molecular circuitry that governs myocardial metabolism.
EXPERIMENTAL PROCEDURES
Animal Models-All protocols concerning animal use were approved by the Institutional Animal Care and Use Committee at Case Western Reserve University and conducted in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Klf15 Ϫ/Ϫ mice have been described previously (23) . Studies were performed with ageand sex-matched littermate controls (12-14 weeks old, male, pure C57Bl/6 background). Mice were housed in a temperature-and humidity-controlled barrier facility with a 12-h light/ dark cycle and ad libitum access to water and standard laboratory rodent chow (Laboratory diet P3000; 4.5% fat by weight, 14% kcal).
Cell Culture-Neonatal rat ventricular myocytes (NRVM) were isolated from 2-day-old rat pups and isolated and maintained under standard conditions as described previously (20, 21, 27) . Isolated NRVM were cultured for 24 -48 h under quiescent conditions by the inclusion of serum-free DMEM supplemented with insulin, transferrin, and selenium prior to experiments. C2C12 myoblasts were purchased from ATCC (Manassas, VA) and grown in DMEM supplemented with 10% FBS. C2C12 myoblasts were passaged prior to reaching 60% confluence to maintain cells in the undifferentiated state. All studies used low passage C2C12 (passages 3-6). P300 Ϫ/Ϫ mouse embryonic fibroblasts (28) were cultured in DMEM supplemented with 10% FBS as described previously (29) .
Plasmids and Adenoviruses-Expression plasmids containing the mouse KLF15 cDNA have been described previously (20) . The Ϫ1.2 kb promoter region of mouse Slc27a1 (Fatp1) was PCR-amplified from purified genomic DNA (Promega) and subcloned into pGL3-basic (Promega). The Pdk4 promoter-luciferase construct was a gift from D. Kelly (30) . For shRNA against mouse/rat Klf15, the hairpin sequence 5Ј-GCGGTAA-GATGTACATCAAACGTGTGCTGTCCGTTTGGTGTAC-ATCTTGCTGC-3Ј (loop sequence is underlined) was subcloned into the pEQ adenoviral shRNA vector (Welgen, Inc.). Recombinant adenoviruses for sh-Klf15 and sh-scrambled were amplified and purified by Welgen, Inc.
Isolated Working Heart-The isolated mouse working heart perfusion was performed at the Washington University Metabolic Core as described previously (31, 32) . In brief, hearts were excised and placed in ice-cold Krebs-Henseleit solution. Retrograde perfusion of the aorta was first performed via the Langendorff method followed by left atrial cannulation. Working mode was maintained in oxygenated buffer containing 0.4 mM palmitate, 5.0 mM glucose, and 100 microunits insulin/ml with a preload pressure of 11.5 mm Hg and afterload pressure of 50 mm Hg. Palmitate and glucose oxidation rates were determined using radiolabeled [ 3 H]palmitate and [U-14 C]glucose, respectively. Samples were collected every 10 min, and 3 H 2 O and 14 CO 2 radioactivity was counted to determine palmitate and glucose oxidation rates, respectively. In addition, functional measurements such as cardiac output, peak systolic pressure, and heart rate were measured as described previously (31) .
Human Left Ventricular Samples-Human left ventricular RNA samples were obtained as described previously (6) . In brief, myocardial specimens were collected before and after left ventricular assisted device (LVAD) implantation and explantation as a bridge to transplantation for end-stage HF patients. Control heart samples were obtained from non-failing hearts as described previously (6) . Fetal left ventricular samples were obtained at the time of elective termination immediately following tissue extraction. The use of all human samples was approved by the Institutional Review Board of Columbia University and Case Western Reserve University (IRB-AAAE7393).
Measurement of Plasma Parameters and Tissue Lipids-Hearts and plasma were rapidly harvested and flash frozen from WT and KO mice. Lipids were extracted from ventricles by the Folch method. Cardiac FA and TG content was quantified by thin layer chromatography by the National Institutes of Health-Mouse Metabolic Phenotyping Core/Lipid Analytic Core at Vanderbilt University. Plasma free fatty acids and TGs were quantified by the Vanderbilt National Institutes of Health Mouse Metabolic Phenotyping Core.
Mitochondrial Physiology and Electron Microscopy-Myocardia of four individual WT or KO mice were pooled for each experiment. The data presented are from four independent experiments. Fresh myocardial subsarcolemmal mitochondria were isolated as described previously (33) . Mitochondrial protein concentration, citrate synthase activity, and oxygen consumption (using a Clark-type oxygen electrode at 30°C) were assayed as described previously (33, 34) . Mouse heart tissue was freshly dissected and rapidly processed for transmission electron microscopy as described previously (35) .
Mitochondrial Genome Quantification-Total tissue DNA was prepared from hearts of WT versus KO mice using the QIAamp DNA minikit (Qiagen) according to the manufacturer's instructions. SYBR Green qPCR of purified DNA was performed using primers specific for the mouse mitochondrial Mt-Cox2 gene. Values were normalized to the nucleus-encoded mouse Rplp0 gene using the ⌬⌬Ct method. Primer sequences are available upon request.
Chromatin Immunoprecipitation-Chromatin isolated from 15 million NRVM were used for each immunoprecipitation. NRVM were infected with empty virus or Ad-KLF15-FLAG, fixed with 1.1% formaldehyde for 10 min, and quenched with 0.125 M glycine for 5 min. Chromatin was extracted and sonicated using a BioRuptor (Diagnode, Sparta, NJ). The sonicated chromatin was immunoprecipitated with 5 g of anti-FLAG(M2) antibodies (Sigma) bound to Dynabeads (Invitrogen) followed by extensive washing and elution. For heart tissue, chromatin isolated from two hearts was pooled for a single immunoprecipitation. Tissue was finely minced in PBS supplemented with protease inhibitors, fixed with 1.1% formaldehyde (10 min), and quenched with 0.125 M glycine (5 min). Tissues were disrupted using a Dounce homogenizer followed by chromatin extraction and sonication with a Bioruptor. Approximately 500 g of chromatin was used in each immunoprecipitation with 5 g of anti-p300 antibody (C-20, Santa Cruz Biotechnology, Inc.) bound to Dynabeads followed by extensive washing and elution. Chromatin was then reverse cross-linked followed by purification of genomic DNA. Target and non-target regions of genomic DNA were amplified by qPCR in both the immunoprecipitates and input samples. For NRVM samples, the rat Alb1 locus was used as a non-target control. For mouse heart tissue samples, the 28 S genomic locus was used as a non-target control. Relative abundance in immunoprecipitates was expressed as the percentage of abundance in input samples as described previously (26, 36) . ChIP primer sequences are available upon request.
RNA Extraction and qPCR-Tissue samples were disrupted/ homogenized in PureZOL TM (Bio-Rad) in a Tissue-lyzer (Qiagen), using stainless steel beads (30 Hz for a total of 4 min). Total RNA was isolated using the Aurum TM (Bio-Rad) RNA isolation kit according to the manufacturer's directions. For cellular samples, total RNA from NRVM was isolated using the high pure RNA isolation kit (Roche Applied Science) according to the manufacturer's directions. For qPCR, total RNA was deoxyribonuclease-treated on-column and transcribed to complementary DNA using iScript TM (Bio-Rad) following the manufacturer's protocol. qPCR was performed with the TaqMan method (using the Roche Universal Probe Library System) on an ABI Step One Plus real-time PCR system. Relative expression was calculated using the ⌬⌬Ct method with normalization to constitutive genes as indicated in each figure. Specific primer/probe sequences are available on request.
Co-Immunoprecipitation-Co-IP was performed from nuclear protein extracts. Nuclear protein from 293 cells or mouse tissues was prepared using the Ne-PER kit (Pierce) according to the manufacturer's instructions. For each IP, 100 -200 g of nuclear protein was loaded in IP dilution buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.2% Nonidet P-40, supplemented with protease inhibitors) and immunoprecipitated with 2-5 g of antibody bound to Dynabeads. Antibodies used for IP were anti-Myc (9E1, Santa Cruz Biotechnology) and goat polyclonal anti-KLF15 (Abcam). Immune complexes were washed extensively and eluted in SDS sample buffer. Immunoprecipitated and input proteins were run on SDS-PAGE and immunoblotted with the following antibodies as indicated: anti-p300 (N-15, Santa Cruz Biotechnology), anti-HA (HA-7, Sigma), anti-Myc (9E10, Santa Cruz Biotechnology), and goat polyclonal anti-KLF15 (Abcam). Secondary HRP-conjugated antibodies and ECL-plus chemiluminescent detection reagent were from Amersham Biosciences.
Microarray Analysis and Bioinformatics-Total ventricular tissue RNA was purified from wild-type and Klf15 Ϫ/Ϫ mice (n ϭ 4), which were subject to an 18-h overnight fast (4 p.m. to 10 a.m. the following morning). Labeling, hybridization, and scanning using an Affymetrix Genechip (Mouse Genome 430A 2.0 Array) were performed at the Harvard Partners Center for Genetics and Genomics. Raw microarray data were subject to background subtraction and multiarray normalization. Microarray data were log-transformed before differential expression analysis using the limma package (37) . Probes with a p value of less than 0.05 after adjusting for false discovery rate using Benjamini and Hochberg method (38) were considered significant in differential expression. Enrichment in biological processes was analyzed using the DAVID bioinformatics suite (39, 40) . The data set was submitted to the NCBI Gene Expression Omnibus with the accession number GSE53231.
Promoter-Luciferase Studies-Transient transfections of the indicated promoter plasmids using cultured NRVM or C2C12 cells at 70% confluence were carried out using Fugene6 (Roche Applied Science and Promega) following the manufacturer's instructions, and bioluminescence was recorded on a Veritas luminometer (Turner Biosystems) as described previously (20, 26) .
Data Analysis-All results are expressed as means, and error bars depict S.E. Statistical analysis of microarray data is described separately above. For experiments comparing the means of two normally distributed groups, two-tailed Student's t test for unpaired data was used. Statistical significance was defined as p Ͻ 0.05.
RESULTS

KLF15 Regulates Myocardial Lipid Utilization-Because
KLF15 has been demonstrated to be important for fasting-induced gluconeogenesis in the liver (24), we first assessed its expression pattern in hearts of adult mice in the fed, fasted, and refed states. As with previously identified metabolic regulators, such as Pdk4 and Fatp1, Klf15 was robustly induced with fasting with a return to baseline after refeeding ( Fig. 1A ), suggesting a role in cardiac metabolic function. Klf15 expression was very low in neonatal mouse hearts and significantly induced with postnatal maturation in a pattern that paralleled other important metabolic genes (Pdk4 and Fatp1) during this transition from neonatal cardiac metabolism (glucose utilization) to that of the adult (predominance of lipid oxidation) (7) (Fig. 1B) . In a similar manner, KLF15 expression was induced during the fetal to adult transition in human heart tissue (Fig. 1C ). Conversely, KLF15 has been shown to be substantially down-regulated in rodent models of heart failure (20, 21) , a pathologic state where myocardial lipid utilization is reduced (5, 6) . Consistent with this rodent data, we found KLF15 to be significantly reduced in failing human hearts with a significant recovery of expression after mechanical unloading with a left ventricular assist device ( Fig. 1D) (6) . Although we have shown that KLF15 functions as a transcriptional repressor of prohypertrophic signaling in cardiomyocytes (20, 21) , the gene networks directly regulated by KLF15 in the myocardium remain largely unknown. Based on the data above, we hypothesized that KLF15 might play an important role in metabolic function of the adult heart.
To establish a tissue-intrinsic role for KLF15 in cardiac metabolism, we performed ex vivo isolated working heart (IWH) studies in wild-type (WT) and Klf15-deficient (KO) hearts. We focused these IWH studies on fatty acid and glucose utilization because these substrates are the major fuel sources in the working mammalian heart (1) . KO hearts had a striking reduction in fatty acid oxidation with a parallel increase in glucose oxidation ( Fig. 2A) . Importantly, there was no significant difference in hemodynamic indices between KO and WT hearts during the IWH experiments (Fig. 2B ). Furthermore, KO hearts are structurally normal and have preserved systolic function under basal conditions (20) . These results suggest that the observed defect in lipid utilization is not occurring during a state of severe contractile dysfunction. In addition, KO mice are characterized by reduced intramyocardial FA and TG abundance (Fig. 3A) , despite elevated plasma concentration of FAs and TGs (Fig. 3B ). This observation was corroborated by electron microscopic examination, which revealed a striking paucity of intramyocellular lipid droplets in the hearts of KO mice (Fig. 3C ). Hence, KLF15 deficient hearts are unable to ade-quately partition plasma lipids despite adequate delivery to the myocardium.
To demonstrate an additional downstream defect in mitochondrial lipid catabolism independent of the above defect in cytosolic lipid bioavailability, we directly assessed substrate utilization in mitochondria freshly isolated from the hearts of WT and KO mice. We did not detect differences in mitochondrial genome copy number in KO hearts (Fig. 3D ). Concordant with this finding, mitochondrial yield was equivalent between WT and KO hearts, thus providing additional confirmation that mitochondrial quantity was unchanged (Fig. 3E ). Furthermore, WT and KO cardiac mitochondria exhibited no significant differences in glutamate oxidation rates, reflecting unaltered function of the electron transport chain (Fig. 3F) . Last, transmission electron microscopy at the mitochondrial level revealed no gross differences in mitochondrial ultrastructure (Fig. 3C) . However, when we directly assessed mitochondrial lipid oxidation rates, we found that freshly isolated mitochondria from KO hearts had a significant defect in fatty acid oxidation (Fig. 3G) .
Thus, in addition to proximal abnormalities in sarcolemmal lipid partitioning (Fig. 3, A and B) , KLF15 is also critical for the distal step of mitochondrial lipid oxidation.
To gain further insight into the broad defects in myocardial lipid utilization seen above, we performed transcriptome-wide gene expression profiling of KO heart tissue. These microarray analyses showed that KO hearts have a transcriptomic signature characterized by a broad and significant reduction in genes critical for myocardial substrate metabolism, including genes involving lipid utilization ( Fig. 4A and supplemental Table 1 ). Because lipids are the dominant fuel source for the heart under physiologic conditions, the above transcriptomic signature and our IWH data ( Fig. 2A ) prompted us to directly assess a broad panel of lipid-related transcripts by qRT-PCR in WT versus KO heart tissue. These analyses confirmed significant reductions in genes encompassing nearly all major components of the myocardial lipid flux pathway, including sarcolemmal FA partitioning/activation, intramyocellular storage, mitochondrial transport and ␤-oxidation, and peroxisomal function (Fig. 4B) . Genes directly involved in the mitochondrial electron transport chain and oxidative phosphorylation were not reduced in KO hearts (Fig. 4C) . Importantly, the observed reductions in lipid flux targets seen in KO hearts occurred without significant alterations in the expression of known transcriptional regulators of myocellular substrate flux and energetics (Fig. 4D) . Moreover, we did not observe significant differences in key genes involved in myocardial glucose uptake and glycolysis (Fig.  4E) (12, 16, 41) . Acute silencing as well as overexpression of KLF15 in cultured neonatal rat cardiomyocytes significantly reduced and augmented, respectively, expression of a parallel panel of lipid flux targets, confirming a cell-autonomous role for KLF15 in cardiomyocyte gene expression ( Fig. 4, G and H) .
KLF15 Transactivates Direct Targets via Recruitment of p300-We next sought to establish the principle that KLF15 could regulate key targets in this pathway via a direct mechanism of action. Pdk4 and Fatp1 (Slc27a1) were used as exemplary targets, given the essential role of these genes in myocellular lipid flux and extensive functional knowledge of their proximal promoters (30, (42) (43) (44) (45) . The proximal promoters of both genes were induced by KLF15 in cultured cardiomyocytes (Fig. 5A ). ChIP analysis in cardiomyocytes confirmed enrichment of KLF15 at conserved KLF response elements on these promoters (Fig. 5B) . Thus, although Fatp1 and Pdk4 are only representative of a larger array of KLF15-regulated metabolic targets, these focused analyses serve to establish the principle that KLF15 can regulate important genes via direct occupancy of target promoters.
In order to gain deeper insight into a generalizable mechanism underlying KLF15-mediated target gene transactivation, we turned to structure-function analyses. We were intrigued by a recent biophysical study that demonstrated significant similarity between the p300-interacting domain of p53 and a homologous domain within the erythroid-specific KLF family member, EKLF/KLF1 (46) . Indeed, inspection of the KLF15 gene revealed a putative p300-interacting transactivation domain (Fig. 5C ) that was highly conserved from humans to zebrafish (Fig. 5D ). The possibility of cooperativity between these two regulators on metabolic targets was further supported by our observation that myocardial Ep300 and Klf15 expression were induced in parallel during fasting and postnatal maturation (Fig. 1, A and B) . Indeed, we observed significant cooperativity between KLF15 and p300 upon induction of target promoters (Fig. 5E ). Studies in p300 Ϫ/Ϫ cells revealed that optimal target gene induction by KLF15 required endogenous p300 (Fig. 5F ). We next demonstrated interaction between epitope-tagged KLF15 and p300 when co-expressed in 293 cells and also confirmed interaction between endogenous KLF15 and p300 in mouse heart and liver tissues (Fig. 6, A-C) . Ablation of the KLF15 putative p300 binding domain (KLF15⌬p300) abrogated the interaction with endogenous p300 (Fig. 6C ) and the cooperative induction of target promoters (Fig. 6D) . Importantly, KLF15⌬p300 remains nucleus-localized and is expressed as a protein of expected mobility with abundance identical to that of identical full-length KLF15 (Fig. 6C ). Finally, ChIP against endogenous p300 in KLF15-deficient mouse heart tissue revealed reduced p300 enrichment in the proximal promoters of target genes (Fig. 6E ). Taken together, the above data establish KLF15 as a direct regulator of the myocardial lipid flux pathway in vivo. In addition, we demonstrate that a major mechanism of KLF15-mediated transactivation involves interaction with p300 and site-specific recruitment of this critical co-activator to target promoters.
DISCUSSION
Our current findings establish KLF15 as a direct and independent regulator of myocardial nutrient flux and thereby introduce an entirely new class of factors (KLFs) as core components of the transcriptional circuitry that governs cardiac metabolism (schematized in Fig. 7 ). Using unbiased gene expression profiling, we elucidate a large number of KLF15-dependent targets in the heart in vivo and confirm its essential role in regulating a transcriptional program essential for efficient myocardial lipid flux. Furthermore, we establish a fundamental molecular mechanism of KLF15-mediated target gene transactivation, which involves its ability to interact with and recruit the chromatin remodeling enzyme p300. Because the mammalian heart's ability to maintain blood flow across a wide range of physiologic and pathophysiologic circumstances depends on tightly coupled control of fuel supply with energy demand (5) , this work suggests that KLF15 is essential for the heart's ability to metabolically adapt to stress. Consistent with this critical role in myocardial adaptation, we have found that Klf15-deficient mice develop dramatically accelerated heart failure after hemodynamically (pressure overload) and neurohormonally (chronic angiotensin II infusion) induced stress (20, 21) . When considered alongside our prior observations that implicate KLF15 as a regulator of fasting hepatic gluconeogenesis and skeletal muscle substrate catabolism (24 -26) , the current work implicates KLF15 as a nodal integrator of nutrient flux across diverse organ systems.
We show that cardiac KLF15, which is robustly induced during physiologic states, such as fasting and postnatal development, cooperates with p300 to regulate key metabolic targets. Previous studies have implicated p300 acetyltransferase as a positive regulator of pathologic cardiomyocyte hypertrophy, possibly via its ability to acetylate prohypertrophic transcription factors, such as GATA4, MEF2, and p53 (21, (47) (48) (49) (50) . Prior work from our group has shown that Klf15 expression is dramatically reduced during pathologic cardiac hypertrophy, an event that releases repression of GATA4, MEF2, and the p300-p53 transcriptional module (20, 21) . Therefore, our current findings, when taken in the context of previously published work, support a model in which increased levels of KLF15 (e.g. during fasting) favor recruitment of p300 to specific metabolic targets, whereas reduced levels of KLF15 (e.g. during pressure overload) decrease expression of these metabolic genes and simultaneously liberate molecules of p300 to co-activate prohy-pertrophic transcription factors, such as GATA4 and MEF2. In this manner, increased levels of KLF15 may recruit rate-limiting quantities of p300 to transactivate its direct targets while simultaneously repressing the function of p300-regulated prohypertrophic transcriptional effectors.
Our IWH experiments show that Klf15-deficient hearts have not only a 47% reduction in palmitate oxidation but also a 32% increase in glucose oxidation rate. These IWH data parallel those observed in Ppara null hearts (15) . Although our studies demonstrate that KLF15, like PPAR␣, directly regulates genes critical for efficient myocardial lipid utilization, there are several potential explanations for the concomitant increase in glucose oxidation rates. We did not observe increased expression of key genes that directly participate in myocardial glucose uptake or glycolysis (Fig. 4E ). However, KO hearts did have reduced expression of Pdk4, an important inhibitor of the pyruvate dehydrogenase complex. Decreased PDK4 would increase pyruvate dehydrogenase activity, leading to increased rates of glucose oxidation. In addition, it is possible that a primary reduction in myocardial long chain fatty acid oxidation rates can secondarily increase glucose oxidation rates via the well described allosteric mechanisms of the Randle cycle (51). Finally, it remains possible that KLF15 might regulate the metabolism of other myocardial fuels (e.g. amino acids) in a manner that could influence glucose homeostasis.
Because cardiac KLF15 is induced during fasting in vivo (Fig.  1A) , delineation of the precise molecular events that govern its expression will provide additional insights into its physiologic (27), a central component of the mammalian circadian clock. Therefore, it is likely that balance between such catabolic and anabolic upstream signals, with additional synchronization via the circadian clock, regulates cardiac KLF15 function. In addition to its newly defined role in cardiac lipid metabolism, KLF15 also regulates the catabolism of skeletal muscle branched chain amino acids, the body's major store of glucogenic precursors (24, 25) . Because cardiac and skeletal muscle share similar substrate flux machinery, it is possible that KLF15 might also regulate myocardial amino acid homeostasis in a manner that influences metabolism of other substrates and cardiac function. Given the intense interest in the interplay between lipid and branched chain amino acid metabolism during physiological and pathophysiological states (56) , it will be interesting to explore whether these aspects of KLF15 function are perturbed in heart failure and other cardiometabolic diseases. Our current work in cardiac metabolism is also interesting to consider alongside our recent observation that KLF15 regulates cardiac repolarization in vivo (27) . Studies in large animal models of heart failure demonstrate that regional electromechanical dyssynchrony is associated with profound changes in genes critical for myocardial lipid and amino acid metabolism (57) . Because KLF15 expression has also been shown to be significantly reduced in rodent and human heart failure (21) with recovery of expression after mechanical unloading (Fig. 1D) , these findings collectively raise the intriguing possibility that myocardial substrate flux and electrical activity might be subject to coordinate control by KLF15 as a form of "metabo-electrical coupling."
KLF15 Regulates Cardiac Lipid Metabolism
Previous studies have identified key members of the nuclear receptor superfamily (e.g. PPARs and ERR␣) as direct regulators of cardiac lipid metabolism (12, 15) . We note that many of the lipid metabolic genes regulated by KLF15 are also known to be PPAR␣ targets in the heart (12) . Furthermore, we find that KLF15-deficient hearts have defects in lipid utilization as prominent as those observed with complete PPAR␣ deficiency (15) . Importantly, these defects in lipid metabolism and target gene expression seen with KLF15 deficiency occur with minimal alteration in expression of PPARs, ERRs, or several other important metabolic regulators (Fig. 4D ). We postulate that KLF15 and nuclear receptors, such as PPAR␣, together exert coordinated control over a subset of important shared targets. Our observation that KLF15 binds and recruits p300 to promoters supports a transactivation model in which KLF15 occupancy favors an open chromatin configuration for the regulatory regions of its direct targets in the lipid flux pathway. It is also possible that the ability of KLF15 to influence intracellular lipid abundance may secondarily affect the bioavailability of endogenous PPAR ligands (13) . Studies exploring potential cross-talk between KLFs and nuclear receptors in cardiac metabolism are an area of ongoing investigation by our group. Interestingly, KLF homologs and PPAR␣-like nuclear receptor genes in C. elegans have recently been shown to both play important roles in lipid metabolism (58, 59) , raising the intriguing possibility that coordinated control of metabolic flux by these two ancient transcription factor families may have been present as early in evolution as the phylum Nematoda. We speculate that functional interactions between KLFs and nuclear receptor networks will emerge as an important theme in our understanding of metabolic plasticity in the myocardium as well as across a broad range of tissues.
